Conversely, evidence also shows that a decrease in exosomal PD-L1 levels is associated with a better clinical outcome after immunotherapy; from that perspective, a decrease in tumor burden may also cause a decrease in extracellular PD-L1 release [62]. Here, CD274 is linked to neoplasm.